Safety of intrauterine devices among women with HIV: a systematic review

Contraception

Volumn 94, Issue 6, 2016, Pages 713-724

  Tepper, Naomi K ^a   Curtis, Kathryn M ^a   Nanda, Kavita ^b   Jamieson, Denise J ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

HIV; Intrauterine device; Pelvic inflammatory disease; Systematic review

Indexed keywords

CLINICAL OUTCOME; CONTRACEPTION; DEVICE SAFETY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; INFECTIOUS COMPLICATION; INTRAUTERINE CONTRACEPTIVE DEVICE; MEDLINE; PELVIC INFLAMMATORY DISEASE; REVIEW; SYSTEMATIC REVIEW; VIRUS SHEDDING; VIRUS TRANSMISSION; HIV INFECTIONS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TRANSMISSION;

CONTRACEPTION; EQUIPMENT SAFETY; FEMALE; HIV INFECTIONS; HUMANS; INTRAUTERINE DEVICES; PELVIC INFLAMMATORY DISEASE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 84995917346     PISSN: 00107824     EISSN: 18790518     Source Type: Journal    
DOI: 10.1016/j.contraception.2016.06.011     Document Type: Review

References (35)

1. [1] CDC, HIV surveillance report, volume 26. Available at http://www.cdc.gov/hiv/library/reports/surveillance/index.html [Accessed June 15, 2016].
2. [2] CDC, U.S. medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep 59:RR-4 (2010), 1–86.
3. [3] Curtis, KM, Nanda, K, Kapp, N, Safety of hormonal and intrauterine methods of contraception for women with HIV/AIDS: a systematic review. AIDS 23:Suppl. 1 (2009), S55–S67.
4. [4] Phillips, SJ, Curtis, KM, Polis, CB, Effect of hormonal contraceptive methods on HIV disease progression: a systematic review. AIDS 27 (2013), 787–794.
5. [5] Polis, CB, Phillips, SJ, Curtis, KM, Hormonal contraceptive use and female-to-male HIV transmission: a systematic review of the epidemiologic evidence. AIDS 27 (2013), 493–505.
6. [6] Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ, 339, 2009, b2535.
7. [7] Harris, RP, Helfand, M, Woolf, SH, Lohr, KN, Mulrow, CD, Teutsch, SM, et al. Current methods of the US preventive services task force: a review of the process. Am J Prev Med 20 (2001), 21–35.
8. [8] Heikinheimo, O, Lehtovirta, P, Suni, J, Paavonen, J, The levonorgestrel-releasing intrauterine system (LNG-IUS) in HIV-infected women-effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 21 (2006), 2857–2861.
9. [9] Lehtovirta, P, Paavonen, J, Heikinheimo, O, Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women. Contraception 75 (2007), 37–39.
10. [10] Morrison, CS, Sekadde-Kigondu, C, Sinei, SK, Weiner, DH, Kwok, C, Kokonya, D, Is the intrauterine device appropriate contraception for HIV-1-infected women?. Br J Obstet Gynaecol 108 (2001), 784–790.
11. [11] Richardson, BA, Morrison, CS, Sekadde-Kigondu, C, Sinei, SK, Overbaugh, J, Panteleeff, DD, et al. Effect of intrauterine device use on cervical shedding of HIV-1 DNA. AIDS 13 (1999), 2091–2097.
12. [12] Sinei, SK, Morrison, CS, Sekadde-Kigondu, C, Allen, M, Kokonya, D, Complications of use of intrauterine devices among HIV-1-infected women. Lancet 351 (1998), 1238–1241.
13. [13] Stringer, EM, Kaseba, C, Levy, J, Sinkala, M, Goldenberg, RL, Chi, BH, et al. A randomized trial of the intrauterine contraceptive device vs hormonal contraception in women who are infected with the human immunodeficiency virus. Am J Obstet Gynecol 197 (2007), 144.e1–144.e8.
14. [14] Stringer, EM, Levy, J, Sinkala, M, Chi, BH, Matongo, I, Chintu, N, et al. HIV disease progression by hormonal contraceptive method: secondary analysis of a randomized trial. AIDS 23 (2009), 1377–1382.
15. [15] Coleman, JS, Mwachari, C, Balkus, J, Sanguli, L, Muliro, A, Agnew, K, et al. Effect of the levonorgestrel intrauterine device on genital HIV-1 RNA shedding among HIV-1-infected women not taking antiretroviral therapy in Nairobi, Kenya. J Acquir Immune Defic Syndr 63 (2013), 245–248.
16. [16] Haddad, LB, Cwiak, C, Jamieson, DJ, Feldacker, C, Tweya, H, Hosseinipour, M, et al. Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate. Contraception 88 (2013), 737–743.
17. [17] Heikinheimo, O, Lehtovirta, P, Aho, I, Ristola, M, Paavonen, J, The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up study. Am J Obstet Gynecol 204 (2011), 126.e1–126.e4.
18. [18] Landolt, NK, Phanuphak, N, Teeratakulpisarn, N, Kriengsinyot, R, Ahluwalia, J, Pinyakorn, S, et al. Uptake and continuous use of copper intrauterine device in a cohort of HIV-positive women. AIDS Care 25 (2013), 710–714.
19. [19] Kakaire, O, Byamugisha, JK, Tumwesigye, NM, Gemzell-Danielsson, K, Clinical versus laboratory screening for sexually transmitted infections prior to insertion of intrauterine contraception among women living with HIV/AIDS: a randomized controlled trial. Hum Reprod 30 (2015), 1573–1579.
20. [20] Comparison of female to male and male to female transmission of HIV in 563 stable couples. European study group on heterosexual transmission of HIV. BMJ 304 (1992), 809–813.
21. [21] Kovacs, A, Wasserman, SS, Burns, D, Wright, DJ, Cohn, J, Landay, A, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 358 (2001), 1593–1601.
22. [22] Mostad, SB, Overbaugh, J, DeVange, DM, Welch, MJ, Chohan, B, Mandaliya, K, et al. Hormonal contraception, vitamin a deficiency, and other risk factors for shedding of HIV-1 infected cells from the cervix and vagina. Lancet 350 (1997), 922–927.
23. [23] Kakaire, O, Byamugisha, JK, Tumwesigye, NM, Gemzell-Danielsson, K, Intrauterine contraception among women living with human immunodeficiency virus: a randomized controlled trial. Obstet Gynecol 126 (2015), 928–934.
24. [24] Huchko, MJ, Woo, VG, Liegler, T, Leslie, H, Smith-McCune, K, Sawaya, GF, et al. Impact of loop electrosurgical excision procedure for cervical intraepithelial neoplasia on HIV-1 genital shedding: a prospective cohort study. Brit J Obstet Gynaecol 120 (2013), 1233–1239.
25. [25] Kietpeerakool, C, Srisomboon, J, Suprasert, P, Phongnarisorn, C, Charoenkwan, K, Cheewakriangkrai, C, et al. Outcomes of loop electrosurgical excision procedure for cervical neoplasia in human immunodeficiency virus-infected women. Int J Gynecol Cancer 16 (2006), 1082–1088.
26. [26] Kietpeerakool, C, Suprasert, P, Srisomboon, J, Outcome of loop electrosurgical excision for HIV-positive women in a low-resource outpatient setting. Int J Gynecol Obstet 105 (2009), 10–13.
27. [27] Stuart, GS, Sheffield, JS, Hill, JB, McIntire, DD, McElwee, B, Wendel, GD, Morbidity that is associated with curettage for the management of spontaneous and induced abortion in women who are infected with HIV. Am J Obstet Gynecol 191 (2004), 993–997.
28. [28] Julkunen, HA, Kaaja, R, Friman, C, Contraceptive practice in women with systemic lupus erythematosus. Brit J Rheumatol 32 (1993), 227–230.
29. [29] Paulen, ME, Folger, SG, Curtis, KM, Jamieson, DJ, Contraceptive use among solid organ transplant patients: a systematic review. Contraception 82 (2010), 102–112.
30. [30] Sanchez-Guerrero, J, Uribe, AG, Jimenez-Santana, L, Mestanza-Peralta, M, Lara-Reyes, P, Seuc, AH, et al. A trial of contraceptive methods in women with systemic lupus erythematosus. New Engl J Med 353 (2005), 2539–2549.
31. [31] Achilles, SL, Creinin, MD, Stoner, KA, Chen, BA, Meyn, L, Hillier, SL, Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol 211 (2014), 489.e1–489.e9.
32. [32] Wright, TC Jr., Subbarao, S, Ellerbrock, TV, Lennox, JL, Evans-Strickfaden, T, Smith, DG, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol 184 (2001), 279–285.
33. [33] Chung, MH, McKenzie, KP, Richardson, BA, John-Stewart, GC, Coombs, RW, De Vuyst, H, et al. Cervical HIV-1 RNA shedding after cryotherapy among HIV-positive women with cervical intraepithelial neoplasia stage 2 or 3. AIDS 25 (2011), 1915–1919.
34. [34] World Health Organization, WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children., 2007 Available at http://www.who.int/hiv/pub/guidelines/HIVstaging150307.pdf [Accessed June 15, 2016].
35. [35] CDC, Revised surveillance case definition for HIV infection-United States, 2014. MMWR Recomm Rep 63:RR-03 (2014), 1–10.